SKB264
merck,daiichi sankyo,astrazeneca,gilead,klus
['$gild', '$dsnky', '$azn', '$mrk']
kelun's anti-trop2 adc skb-264 / mk-2870, which $mrk licensed along with other adcs for $175m #asco23 $azn $gild $dsnky 
Once had a blue tick. Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.